



38. (Amended) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis comprising the step of administering to the patient an amount effective for the treatment of seborrheic dermatitis of a 1-hydroxy-2-pyridone of formula I, wherein the 1-hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt:



where R^1 , R^2 , and R^3 , which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R^4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:



where:

- X is S or O;
- Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;
- Z is a single bond, or

LAW OFFICES
REGAN, HENDERSON,
RABOW, GARRETT
& DUNNER, L.L.P.
100 I STREET, N.W.
WASHINGTON, D.C. 20005
202-408-4000

a linking radical comprising

- (1) O, or
- (2) S, or
- (3) $-\text{CR}_2-$, where R is H or $(\text{C}_1\text{-C}_4)$ -alkyl, or
- (4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain, which optionally further comprises one or more of the following:

- (i) a carbon-carbon double bond, and
- (ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,

in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H, $(\text{C}_1\text{-C}_4)$ -alkyl, or a mixture thereof;

and

Ar is an aromatic ring system having one or two rings which are optionally substituted by one, two, or three radicals, which may be identical or different, which are halogen, methoxy, $(\text{C}_1\text{-C}_4)$ -alkyl, trifluoromethyl, or trifluoromethoxy, wherein the 1-hydroxy-2-pyridone of formula I or the pharmaceutically acceptable salt thereof is administered to the patient in a pharmaceutical composition, the pharmaceutical composition further comprising at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants, and mixtures thereof;

with the proviso that the 1-hydroxy-2-pyridone of formula I is not 6-(4-(4-chlorophenoxy)-phenoxy)methyl)-1-hydroxy-4-methyl-2-pyridone, 1-hydroxy-4-

methyl-6-cyclohexyl-2-pyridone, or a pharmaceutically acceptable salt of either of the foregoing.

39. (Amended) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 49 in which the 1-hydroxy-2-pyridone of formula I comprises Ar as a bicyclic system derived from biphenyl, diphenylalkane, or diphenyl ether.

40. (Amended) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 49 in which the 1-hydroxy-2-pyridone of formula I comprises a cyclohexyl radical in the R⁴ position.

41. (Amended) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 49 in which the 1-hydroxy-2-pyridone of formula I comprises an octyl radical of the formula -CH₂-CH(CH₃)-CH₂-C(CH₃)₃ in the R⁴ position.

42. (Amended) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 49 in which the 1-hydroxy-2-pyridone of formula I is 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)pyridone, or a pharmaceutically acceptable salt thereof.

48. (Amended) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 49 in which the pharmaceutical

LAW OFFICES
NEGAN, HENDERSON, II
ARABOW, GARRETT,
& DUNNER, L.L.P.
300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000

composition further comprises a mixture of at least two surfactants, which are identical or different, and are anionic, cationic, nonionic, and amphoteric surfactants.

49. (Amended) A method of treating a human or animal patient in need of treatment for seborrheic dermatitis as claimed in claim 38 in which the pharmaceutical composition has a pH from about 4.5 to about 6.5.

REMARKS

I. Status of the Claims

Claims 38-42 and 48-49 are pending. Claim 49 depends from independent claim 38, and all other claims depend from claim 49. The claims have been amended without prejudice to pursuing canceled or deleted subject matter in a continuation application, without disclaimer of any subject matter, and without acquiescence in any rejection, objection, or requirement of record in this application. Specifically, claim 38 has been amended to include the subject matter of claims 43-47. Claims 43-47 and 50-52 have been canceled.

Support for these amendments can be found throughout the specification and claims as originally filed. Care has been taken so that no new matter has been introduced into this application.

Applicants have also excluded 6-(4-(4-chlorophenoxy)-phenoxyethyl)-1-hydroxy-4-methyl-2-pyridone and 1-hydroxy-4-methyl-6-cyclohexyl-2-pyridone from the scope of the claimed invention without prejudice, disclaimer, or acquiescence. Specifically, a proviso was added to claim 38, and claim 42 was amended, to exclude these two 1-hydroxy-2-pyridones. Applicants are simply claiming less than the full

LA OFFICES
NEGAN, HENDERSON,
ARABOW, GARRETT,
& DUNNER, L.L.P.
300 I STREET, N. W.
SHINGTON, DC 20005
202-408-4000